Related Experiment Video
Updated: Aug 3, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Peptide leukotriene receptor antagonism in myocardial ischaemia and reperfusion
1Department of Medicine, University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Stratford 08084.
Insights
The peptide leukotriene receptor antagonist LY-171883 significantly reduced myocardial injury during reperfusion in cats. This indicates peptide leukotrienes play a role in extending ischaemic damage and post-ischaemic dysfunction.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Pathophysiology
Background:
- Myocardial ischaemia-reperfusion injury is a significant clinical problem.
- Peptide leukotrienes (PLTs) are implicated in inflammatory processes and tissue damage.
Purpose of the Study:
- To investigate the role of PLTs in myocardial injury during reperfusion.
- To evaluate the efficacy of the PLT receptor antagonist LY-171883 in reducing ischaemia-reperfusion injury.
Main Methods:
- Adult male cats underwent coronary artery occlusion followed by reperfusion.
- The PLT receptor antagonist LY-171883 was administered during reperfusion.
- Myocardial injury was assessed by infarct size, creatine kinase, and neutrophil infiltration (myeloperoxidase activity).
Main Results:
- LY-171883 treatment significantly reduced the necrotic area of the myocardium (48% vs 29% of area at risk).
- Creatine kinase activity was higher in the area at risk in the drug-treated group, indicating less damage.
- Neutrophil infiltration, measured by myeloperoxidase activity, was not significantly reduced by LY-171883.
Conclusions:
- LY-171883 demonstrated a protective effect against myocardial ischaemia-reperfusion injury.
- These findings support a role for PLTs in the extension of ischaemic damage and post-ischaemic ventricular dysfunction.
Objective:
The aim was to investigate the role of peptide leukotrienes in the pathophysiology of myocardial injury during reperfusion of previously ischaemic myocardium.
Methods:
Adult male cats (2.9-5.4 kg) were subjected to left anterior descending coronary artery occlusion for 3 h followed by 3 h of reperfusion. The peptide leukotriene receptor antagonist, LY-171883, was given intravenously only during the reperfusion period (3 mg.kg-1 bolus; 3 mg.kg-1 x h-1 infusion). Ischaemic injury was assessed by nitroblue tetrazolium staining and tissue creatine kinase activity; neutrophil infiltration was determined by myeloperoxidase activity of myocardial homogenates.
Results:
There was no significant difference at any time point in the experimental protocol between mean arterial blood pressure or pressure-rate index in cats given LY-171883 (3 mg.kg-1) and cats given vehicle. The area at risk of infarction (AAR) was 24(SEM 2)% for vehicle treated cats and 22(2)% for the drug treated cats. The necrotic area was 48(5)% of the AAR for the vehicle group but only 29(5)% of the AAR for the group given LY-171883 (p < 0.02). Left ventricular maximum +dP/dt tended to be higher with drug treatment compared to vehicle at the end of the reperfusion period. Tissue from the area at risk was assayed for creatine kinase activity and neutrophil specific myeloperoxidase activity as an index of the accumulation of neutrophils in this region. Creatine kinase activity was significantly higher (p < 0.05) in the AAR for drug nu vehicle treated cats following reperfusion, confirming the histochemical analysis. Myeloperoxidase activity increased approximately 12-fold in the AAR of cats receiving vehicle. LY-171883 did not reduce the myeloperoxidase activity significantly in the area at risk.
Conclusions:
LY-171883 has a protective effect in ischaemia-reperfusion injury to the myocardium. These findings suggest a role for peptide leukotrienes both in the extension of ischaemic damage and in post-ischaemic ventricular dysfunction during reperfusion.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
09:53Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Myocarditis III: Medical Management